Metraipolis › archive › dc_a13655516f13

Cost-effectiveness analysis of pembrolizumab versus chemotherapy in advanced non-small cell lung cancer in China based on real-world studies — Europe PMC PMID:41152654

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41152654
DOI
10.1007/s00432-[numero omesso]-6
License (as archived)
solo-consultazione
Archived
2026-11-09T00:20:59.339Z
SHA-256 of the archived text
20a0b75a30252d6174a66d0c08559dbbc5905b7e7e4fbbbd73dc80abacf1a1f8
Stable URL of this page
https://metraipolis.com/documento/dc_a13655516f13

How to cite

Cost-effectiveness analysis of pembrolizumab versus chemotherapy in advanced non-small cell lung cancer in China based on real-world studies — Europe PMC PMID:41152654 — Europe PMC (en), https://europepmc.org/article/MED/41152654 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a13655516f13 (Metraipolis archive dc_a13655516f13, sha256 20a0b75a30252d6174a66d0c08559dbbc5905b7e7e4fbbbd73dc80abacf1a1f8)
BibTeX
@misc{dca13655516f13,
  title = {Cost-effectiveness analysis of pembrolizumab versus chemotherapy in advanced non-small cell lung cancer in China based on real-world studies — Europe PMC PMID:41152654},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41152654},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a13655516f13; sha256 20a0b75a30252d6174a66d0c08559dbbc5905b7e7e4fbbbd73dc80abacf1a1f8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41152654. Agents can read the archived copy with the MCP tool read_document.